Press release
Investigation announced for Long-Term Investors in NASDAQ: SESN shares over possible Wrongdoing at Sesen Bio, Inc.
An investigation on behalf of current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares.
Investors who are current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SESN stocks follows a lawsuit filed against Sesen Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SESN stocks, concerns whether certain Sesen Bio directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants failed to disclose to investors, that Sesen Bio’s clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as “major”, that three of Sesen Bio’s clinical investigators were found guilty of “serious noncompliance,” including “back-dating data”, that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum, that Sesen Bio’s clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury, that, as a result of the foregoing, the Company’s BLA for Vicineum was not likely to be approved, that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in NASDAQ: SESN shares over possible Wrongdoing at Sesen Bio, Inc. here
News-ID: 2460865 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for Sesen
BCG-unresponsive NMIBC market is projected to reach $4.1 billion by 2034
Bladder cancer is among the most common urologic malignancies worldwide, with non-muscle invasive bladder cancer (NMIBC) representing approximately 70-75% of all new cases. Standard first-line therapy involves transurethral resection followed by intravesical instillation of Bacillus Calmette-Guérin (BCG). While effective in many cases, a significant subset of patients becomes BCG-unresponsive, meaning their disease progresses or recurs despite adequate treatment. This presents a serious clinical challenge, as these patients are at high…
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
Non-Muscle Invasive Bladder Cancer Market: Epidemiology, Therapies, Companies, D …
Non-Muscle Invasive Bladder Cancer therapies are expected to boost the Non-Muscle Invasive Bladder Cancer Market in the upcoming years.
DelveInsight has launched a new report on "Non-Muscle Invasive Bladder Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer, historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Non-Muscle Invasive Bladder Cancer Pipeline Analysis (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Non-Muscle Invasive Bladder Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Non-Muscle Invasive Bladder Cancer…
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trial Analysis and NDA App …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including Non Muscle Invasive Bladder Cancer clinical trial and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration,…
Deadline on October 18th coming up in Lawsuit for Investors in Sesen Bio, Inc. ( …
A deadline is coming up on October 18, 2021 in the lawsuit filed for certain investors of Sesen Bio, Inc. (NASDAQ: SESN) over alleged securities laws violations by Sesen Bio, Inc..
Investors who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and there are strict and short deadlines running. Deadline: October 18, 2021. NASDAQ: SESN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
